Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Q1 Losses Up on Increased Spending

Premium

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week reported its first-quarter financial results, posting a jump in its net loss due to higher costs associated with drug development and its recently completed initial public offering.

For the three-month period ended March 31, 2014, Dicerna's net loss climbed to $10.8 million from $3.8 million in the same period a year earlier.

Research and development spending rose to $5.3 million from $2.4 million, largely due to the initiation of Phase I testing for the company's RNAi cancer drug DCY-MYC in April, as well as continued work on its primary hyperoxaluria 1 therapy DCR-PH1, which is slated to enter human trials early next year.

General and administrative expenses increased to $2.8 million from $1.1 million, reflecting Dicerna's costs of completing its IPO in January.

At the end of the first quarter, Dicerna had cash and cash equivalents totaling $133.8 million.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.